#JPM20 ex­clu­sive: Olivi­er Brandi­court fol­lows the Big Phar­ma CEO path to pri­vate eq­ui­ty, join­ing Black­stone ahead of a mam­moth fund de­but

Last week
People
R&D

Fra­zier clos­es 12th fund in 30 years, with $617M to bet on cell/gene ther­a­py, Big Phar­ma spin­offs and more

Last week
Venture

Neon Ther­a­peu­tics makes one last re­treat, sell­ing it­self cheap in a bar­gain base­ment M&A deal

Last week
Deals
R&D

Bio­phar­ma's Chi­na plan gets a boost from patent pro­tec­tions sealed in now of­fi­cial trade deal

Last week
China
Regulatory

Gov­ern­ment spend­ing bill tweak means 3 more NDAs will be­come BLAs, FDA says

Last week
Regulatory

GSK, Pfiz­er con­tra­dict on the fu­ture of con­sumer health JV — re­port

Last week
Pharma

#JPM20: Af­ter a year of NASH col­laps­es, all eyes on two biotechs

Last week
R&D

Video Re­play: End­points at #JPM20 — news­mak­ers on deal­mak­ing, pric­ing and man­u­fac­tur­ing

Last week
Publisher's note

Cel­gene ex­ec jumps to head blue­bird bio ops in Eu­rope, where its $1.8M gene ther­a­py Zyn­te­glo is now avail­able

Last week
People

FDA grants pri­or­i­ty re­view for Rubra­ca; Arpeg­gio snags $3.2M in seed fi­nanc­ing

Last week
Protocols

FDA staff high­lights neu­ro­log­i­cal safe­ty con­cerns with Durec­t's pain drug

Last week
Regulatory

Take­da hops on­to $61M round for CRISPR play­er syn­the­siz­ing Cas9 al­ter­na­tives

Last week
Startups
Venture

War­ren and Klobuchar say they can low­er drug prices with­out Con­gress’ help

Last week
People
Pharma

Gala­pa­gos beefs up its fi­bro­sis pipeline, las­so­ing 4 more pro­grams and tak­ing a stake in small Cana­di­an part­ner

Last week
Deals

UK's NICE is­n't con­vinced by Mer­ck­'s Keytru­da in head and neck can­cer

Last week
Regulatory

Nek­tar aban­dons opi­oid drug af­ter a unan­i­mous 27-0 re­buff from FDA ad­comm

Last week
R&D

UPMC ven­ture arm ear­marks $1B in­vest­ment in life sci­ences

Last week
Venture

Ipsen re­cruits Steven Hilde­mann as CMO; Eli Lil­ly of­fers two more low-cost in­sulin op­tions

Last week
Protocols

Four years af­ter 'moon­shot' launch, Patrick Soon-Sh­iong has a big re­veal: a sin­gle pa­tient

Last week
R&D

Ab­b­Vie's Skyrizi hangs No­var­tis' Cosen­tyx out to dry in head-to-head pso­ri­a­sis study

Last week
Pharma

#JPM20: 'The NPV is al­ways wrong.' Take­da preps an­oth­er spin­out — this time on psych

Last week
Pharma
R&D

Roche aims to 'un­der­whelm' with ris­diplam price as it en­ters SMA ri­val­ry with Bio­gen, No­var­tis — re­port

Last week
Pharma

‘Clin­i­cal su­pe­ri­or­i­ty’: di­azepam nasal spray il­lus­trates FDA pa­ra­me­ters for or­phan drug ex­clu­siv­i­ty

Last week
R&D
Regulatory

Still to be ap­proved in­clisir­an gets red car­pet treat­ment by UK's NHS in deal with No­var­tis

Last week
Deals
First page Previous page 123456 Next page Last page